CN EN

BioDuro-Sundia

A stellar compliance record following global standards

BioDuro-Sundia, an Advent International portfolio company is a trusted, leading contract research, development, and manufacturing organization (CRDMO) with over 28 years of expertise. Global headquarter in Irvine, California, our global presence spans 7 sites across 6 cities, totaling nearly 3,000 employees. Specializing in small and large molecule discovery, development, scale-up and manufacturing, we offer fully integrated services from target identification to commercial drug product manufacturing.
Learn more

Fully Integrated CRDMO

One stop shop built to accelerate your timelines

Discovery

Hit Generation

Lead Optimization

Candidate Selection

Learn more

Drug Substance

Scale Up g → kg

API, RSMs & Intermediates

IND Filing (FDA, NMPA and others)

Learn more

Drug Product

Solubility Enhancement

Solid Oral Dosage Forms

Clinical & Commercial

Learn more

Platforms

Cutting-edge platforms and integrated solutions for first-in-class and innovative drug discovery, development and manufacturing

Learn more

Discover drugs faster with our comprehensive
in vitro evaluation platform

Bioavailability enhancement

Integrated services under one roof: synthetic chemistry, biology, DMPK, more.

Our one stop shop platform seamlessly
integrates preclinical research services

Find your next hit with the BioDuro-Sundia
fragment screening platform

Tailored engine for small molecular drug discovery
Unlock exponential possibilities screening billions of small molecules

Advanced preclinical models for NASH
Clinical relevance, shortened timelines

Quick collection with vast number
of compounds to speed drug discovery

Delayed, sustained, and custom release

News & Resources

The latest news about BioDuro-Sundia

Learn more

Company News

BioDuro-Sundia’s Partner, DigmBio Announced IND Clearance from Korea MFDS for its Selective PARP1 Inhibitor DM5167

Shanghai, March 26, 2024 – BioDuro-Sundia's partner, DigmBio, a South Korean biotechnology company, announced its selective PARP1 inhibitor for the treatment of triple-negative breast cancer has b
March 26, 2024

Work and careers

Build your career with BioDuro-Sundia

Our customer-oriented, science-driven, flexible, and people-focused culture enables us to provide top-tier integrated service as well as attract and retain talents, ensuring high-quality value delivery.

Learn more
Register Now!
Webinar: New Modality - Peptides Innovations and a Comprehensive Synthetic Peptide Drug Discovery Platform
June 19, 2024 at 10am ET / 07am PT / 04pm CET
View more
0.201445s